Callan Family Office LLC Invests $1.66 Million in Ralliant Corporation $RAL

Callan Family Office LLC acquired a new position in shares of Ralliant Corporation (NYSE:RAL - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 22,588 shares of the company's stock, valued at approximately $1,663,000.

Several other hedge funds have also modified their holdings of the stock. Cetera Investment Advisers purchased a new position in Ralliant during the second quarter worth approximately $700,000. Russell Investments Group Ltd. purchased a new stake in shares of Ralliant during the 2nd quarter valued at $1,465,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Ralliant during the 2nd quarter valued at $39,000. First Trust Advisors LP acquired a new stake in shares of Ralliant during the 2nd quarter worth $2,013,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Ralliant during the 2nd quarter worth $326,000.

Ralliant Stock Up 0.2%

RAL stock opened at $63.72 on Monday. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $7.05 billion, a P/E ratio of -5.87, a PEG ratio of 2.36 and a beta of 1.61. The firm has a 50 day simple moving average of $68.94 and a 200-day simple moving average of $55.94.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The firm had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities research analysts predict that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant's payout ratio is presently -1.84%.

Insider Transactions at Ralliant

In related news, SVP Karen M. Bick sold 6,062 shares of Ralliant stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the completion of the transaction, the senior vice president directly owned 31,668 shares in the company, valued at approximately $2,280,096. This trade represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of Ralliant stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the transaction, the chief executive officer owned 251,967 shares of the company's stock, valued at $18,088,710.93. This trade represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on RAL shares. Evercore started coverage on Ralliant in a report on Tuesday, June 9th. They issued an "outperform" rating and a $80.00 target price on the stock. Zacks Research upgraded Ralliant from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, June 30th. Citigroup upped their price target on Ralliant from $81.00 to $82.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Morgan Stanley lifted their price objective on Ralliant from $68.00 to $85.00 and gave the company an "overweight" rating in a research note on Tuesday, June 23rd. Finally, Barclays upped their price target on shares of Ralliant from $52.00 to $67.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $75.70.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source